May 20, 2014

Post-market drug safety and effectiveness in ankylosing spondylitis (AS)

Query 10-22b: The effects of Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Ankylosing Spondylitis (AS)

Ankylosing spondylitis (AS) is a chronic, progressive, inflammatory type of arthritis that affects up to 1 percent of Canadians. Therapy options are limited, especially for patients with active and severe disease. Nonsteroidal anti-inflammatory drugs (NSAIDs, e.g. Naproxen) are used along with disease-modifying anti-rheumatic drugs (DMARDs, e.g. methotrexate).

Unfortunately there is relatively little published evidence to help physicians and their patients choose which DMARDs to use in which AS patients, under which circumstances. In this catalyst grant, we based our analyses on data prospectively collected on patients enrolled in a large AS patient cohort.

The main clinical outcomes are measured by validated measures of disease activity, functional limitation, and quality of life. Data on infections requiring hospitalizations are being used to evaluate safety.

We presented the results at the Canadian Rheumatology Association (CRA) meeting in Quebec City, Quebec in February 2015, and the EUropean League Against Rheumatism (EURLA) meeting in Rome, Italy in June 2015.

Moura et al. Persistence of Anti-TNF and nbDMARD use in a Population-Based Sample of Ankylosing Spondylitis in Quebec. JRheum #40 Canadian Rheumatology Association (CRA) Annual Scientific Meeting. Quebec City, Canada. 4-7 February 2015.

Moura et al. Risk of hospitalized serious infection in spondylitis ankylosing patients using nbDMARD or Anti-TNF.  Ann rheum dis 2015; 74(suppl2): 266. Annual European Congress of Rheumatology EULAR. Rome, Italy. 10-13 June 2015.

Moura C, Rahme E, Maksymowych W, Abrahamowicz M, Bessette L, Bernatsky S. Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infections in ankylosing spondylitis (AS).  Scandinavian Journal of Rheumatology. 2018 Aug;1-7.

For more information contact: Jessica (Lifang) Wang. Research Coordinator. [email protected]   514.934.1934 ext.44718